Tiago Fauth
Stock Analyst at Wells Fargo
(3.05)
# 1,326
Out of 5,090 analysts
152
Total ratings
42.24%
Success rate
1.17%
Average return
Main Sectors:
Stocks Rated by Tiago Fauth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Overweight | $171 → $217 | $204.00 | +6.37% | 9 | Oct 31, 2025 | |
| WVE Wave Life Sciences | Maintains: Overweight | $21 → $18 | $7.49 | +140.32% | 4 | Sep 4, 2025 | |
| UTHR United Therapeutics | Maintains: Equal-Weight | $295 → $414 | $489.31 | -15.39% | 7 | Sep 3, 2025 | |
| MNKD MannKind | Maintains: Overweight | $9 → $10 | $5.68 | +76.06% | 2 | Sep 3, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $79 → $73 | $77.26 | -5.51% | 5 | Aug 20, 2025 | |
| LQDA Liquidia | Maintains: Overweight | $25 → $31 | $34.41 | -9.91% | 3 | Aug 13, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $333 → $395 | $458.12 | -13.78% | 7 | Aug 1, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $88 → $65 | $36.38 | +78.67% | 8 | Jul 10, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $67 → $76 | $73.64 | +3.20% | 1 | Jun 30, 2025 | |
| SVRA Savara | Maintains: Overweight | $8 → $7 | $6.50 | +7.69% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $112 → $101 | $19.92 | +407.03% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $3 | $1.21 | +147.93% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $21.69 | +19.87% | 6 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $17 | $9.90 | +71.72% | 1 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $75 | $93.29 | -19.61% | 1 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $62 | $8.72 | +611.01% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $89 | $205.44 | -56.68% | 16 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $51 | $32.02 | +59.28% | 3 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $120 | $53.40 | +124.72% | 7 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $4 | $22.84 | -82.49% | 4 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $3.58 | +291.06% | 4 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $300 | $79.99 | +275.05% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $11.95 | +117.57% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $28 | $3.56 | +686.52% | 7 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $81 | $23.63 | +242.78% | 11 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $0.82 | +871.11% | 5 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $4.22 | +231.75% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $34 | $1.42 | +2,294.37% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $150 | $27.46 | +446.25% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $44.36 | -34.63% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $1.95 | +566.67% | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $13 | $2.42 | +437.19% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2.5 → $2 | $1.06 | +88.68% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $297 → $340 | $901.17 | -62.27% | 3 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $265 → $259 | $329.89 | -21.49% | 1 | Apr 28, 2021 |
Insmed
Oct 31, 2025
Maintains: Overweight
Price Target: $171 → $217
Current: $204.00
Upside: +6.37%
Wave Life Sciences
Sep 4, 2025
Maintains: Overweight
Price Target: $21 → $18
Current: $7.49
Upside: +140.32%
United Therapeutics
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $295 → $414
Current: $489.31
Upside: -15.39%
MannKind
Sep 3, 2025
Maintains: Overweight
Price Target: $9 → $10
Current: $5.68
Upside: +76.06%
PTC Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $79 → $73
Current: $77.26
Upside: -5.51%
Liquidia
Aug 13, 2025
Maintains: Overweight
Price Target: $25 → $31
Current: $34.41
Upside: -9.91%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $333 → $395
Current: $458.12
Upside: -13.78%
Ultragenyx Pharmaceutical
Jul 10, 2025
Maintains: Overweight
Price Target: $88 → $65
Current: $36.38
Upside: +78.67%
BridgeBio Pharma
Jun 30, 2025
Maintains: Overweight
Price Target: $67 → $76
Current: $73.64
Upside: +3.20%
Savara
May 28, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $6.50
Upside: +7.69%
Mar 21, 2025
Maintains: Overweight
Price Target: $112 → $101
Current: $19.92
Upside: +407.03%
Mar 4, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $1.21
Upside: +147.93%
Feb 27, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $21.69
Upside: +19.87%
Feb 20, 2025
Maintains: Overweight
Price Target: $18 → $17
Current: $9.90
Upside: +71.72%
Aug 22, 2024
Initiates: Overweight
Price Target: $75
Current: $93.29
Upside: -19.61%
Aug 11, 2023
Maintains: Outperform
Price Target: $63 → $62
Current: $8.72
Upside: +611.01%
Jun 14, 2023
Assumes: Neutral
Price Target: $89
Current: $205.44
Upside: -56.68%
Jun 14, 2023
Assumes: Outperform
Price Target: $51
Current: $32.02
Upside: +59.28%
Jun 14, 2023
Assumes: Outperform
Price Target: $120
Current: $53.40
Upside: +124.72%
May 23, 2023
Reiterates: Underperform
Price Target: $4
Current: $22.84
Upside: -82.49%
May 16, 2023
Reiterates: Outperform
Price Target: $14
Current: $3.58
Upside: +291.06%
May 16, 2023
Reiterates: Outperform
Price Target: $300
Current: $79.99
Upside: +275.05%
May 11, 2023
Reiterates: Outperform
Price Target: $26
Current: $11.95
Upside: +117.57%
May 5, 2023
Maintains: Outperform
Price Target: $34 → $28
Current: $3.56
Upside: +686.52%
May 5, 2023
Maintains: Neutral
Price Target: $70 → $81
Current: $23.63
Upside: +242.78%
Mar 24, 2023
Reiterates: Neutral
Price Target: $8
Current: $0.82
Upside: +871.11%
Mar 23, 2023
Reiterates: Outperform
Price Target: $14
Current: $4.22
Upside: +231.75%
Mar 10, 2023
Maintains: Outperform
Price Target: $38 → $34
Current: $1.42
Upside: +2,294.37%
Mar 10, 2023
Reiterates: Outperform
Price Target: $150
Current: $27.46
Upside: +446.25%
Jan 26, 2023
Initiates: Outperform
Price Target: $29
Current: $44.36
Upside: -34.63%
Dec 16, 2022
Initiates: Outperform
Price Target: $13
Current: $1.95
Upside: +566.67%
Nov 18, 2022
Downgrades: Neutral
Price Target: $25 → $13
Current: $2.42
Upside: +437.19%
May 13, 2022
Maintains: Underperform
Price Target: $2.5 → $2
Current: $1.06
Upside: +88.68%
Dec 20, 2021
Maintains: Neutral
Price Target: $297 → $340
Current: $901.17
Upside: -62.27%
Apr 28, 2021
Maintains: Outperform
Price Target: $265 → $259
Current: $329.89
Upside: -21.49%